AZD6765 for Treatment Resistant Depression

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Depression

Treatments: Drug: AZD6765

Study type: Interventional

Funder types: Industry

Identifiers

NCT00491686

D6702C00001

Details and patient eligibility

About

The purpose of this study is to determine whether treatment with AZD6765 will have an antidepressant effect with patients who have treatment resistant depression.

Enrollment: 34 patients

Sex: All

Ages: 21 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of Depression
• Inadequate response to an adequate course of antidepressants

Exclusion criteria

• Psychiatric disorder other than depression
• Pregnancy or lactation
• Current diagnosis of cancer

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind